Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

@article{Figgitt2000FluvoxamineAU,
  title={Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.},
  author={David P. Figgitt and Karen J. McClellan},
  journal={Drugs},
  year={2000},
  volume={60 4},
  pages={925-54}
}
UNLABELLED Fluvoxamine is a potent and selective serotonin reuptake inhibitor (SSRI) that has little or no effect on other monoamine reuptake mechanisms. Relative to other SSRIs, fluvoxamine is a weak inhibitor of cytochrome P450 (CYP) 2D6, a moderate inhibitor of CYP2C19 and CYP3A4 and a potent inhibitor of CYP1A2. In randomised, double-blind trials. fluvoxamine 100 to 300 mg/day for 6 to 10 weeks significantly reduced symptoms of obsessive-compulsive disorder (OCD) compared with placebo… CONTINUE READING